Metraipolis › archive › dc_e449138c355f

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer — Europe PMC PMID:41294658

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41294658
DOI
10.3390/curroncol32110596
License (as archived)
solo-consultazione
Archived
2026-11-09T02:00:50.922Z
SHA-256 of the archived text
68903039cf1cb075b1700ebc83ddbf004e61503b5cd17fd8a9abd9b0e6681b7f
Stable URL of this page
https://metraipolis.com/documento/dc_e449138c355f

How to cite

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer — Europe PMC PMID:41294658 — Europe PMC (en), https://europepmc.org/article/MED/41294658 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e449138c355f (Metraipolis archive dc_e449138c355f, sha256 68903039cf1cb075b1700ebc83ddbf004e61503b5cd17fd8a9abd9b0e6681b7f)
BibTeX
@misc{dce449138c355f,
  title = {Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer — Europe PMC PMID:41294658},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41294658},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e449138c355f; sha256 68903039cf1cb075b1700ebc83ddbf004e61503b5cd17fd8a9abd9b0e6681b7f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41294658. Agents can read the archived copy with the MCP tool read_document.